Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.

Abstract

Over the past decade, targeted therapies such as BRAF inhibitors, MEK inhibitors and immunotherapies such as anti-CTLA4 and anti-PD1 antibodies have emerged as novel treatments of advanced melanoma. Along with increased use of these therapies, a range of cutaneous adverse events have also emerged, varying from more serious and frequent cutaneous squamous… (More)
DOI: 10.1016/j.ad.2016.05.019

Topics

Cite this paper

@article{Hwang2017CutaneousAE, title={Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.}, author={Shelley Ji Eun Hwang and Rachael M Anforth and Giuliana Carlos and Pablo Fern{\'a}ndez-Pe{\~n}as}, journal={Actas dermo-sifiliograficas}, year={2017}, volume={108 1}, pages={6-16} }